JP6937984B2 - ペグ化ｉｌ−１１の組成物および方法 - Google Patents

ペグ化ｉｌ−１１の組成物および方法 Download PDF

Info

Publication number
JP6937984B2
JP6937984B2 JP2017565038A JP2017565038A JP6937984B2 JP 6937984 B2 JP6937984 B2 JP 6937984B2 JP 2017565038 A JP2017565038 A JP 2017565038A JP 2017565038 A JP2017565038 A JP 2017565038A JP 6937984 B2 JP6937984 B2 JP 6937984B2
Authority
JP
Japan
Prior art keywords
polypeptide chain
peg
modified
induced
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017565038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508580A5 (cg-RX-API-DMAC7.html
JP2018508580A (ja
Inventor
ユ，クォ‐ミン
チョオ，クィ‐リム
フォック，マンソン
ラウ，ジョンソン，イゥ‐ナム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nansha Biologics Hong Kong Ltd
Original Assignee
Nansha Biologics Hong Kong Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nansha Biologics Hong Kong Ltd filed Critical Nansha Biologics Hong Kong Ltd
Publication of JP2018508580A publication Critical patent/JP2018508580A/ja
Publication of JP2018508580A5 publication Critical patent/JP2018508580A5/ja
Priority to JP2021120139A priority Critical patent/JP2021176875A/ja
Application granted granted Critical
Publication of JP6937984B2 publication Critical patent/JP6937984B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017565038A 2015-03-03 2016-03-01 ペグ化ｉｌ−１１の組成物および方法 Active JP6937984B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021120139A JP2021176875A (ja) 2015-03-03 2021-07-21 ポリエチレングリコール（ｐｅｇ）−インターロイキン１１（ｉｌ−１１）コンジュゲートを生成するための反応中間体、および、ｐｅｇ−ｉｌ−１１コンジュゲートを精製する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562127748P 2015-03-03 2015-03-03
US62/127,748 2015-03-03
PCT/US2016/020294 WO2016140983A1 (en) 2015-03-03 2016-03-01 Compositions and methods for pegylated il-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021120139A Division JP2021176875A (ja) 2015-03-03 2021-07-21 ポリエチレングリコール（ｐｅｇ）−インターロイキン１１（ｉｌ−１１）コンジュゲートを生成するための反応中間体、および、ｐｅｇ−ｉｌ−１１コンジュゲートを精製する方法

Publications (3)

Publication Number Publication Date
JP2018508580A JP2018508580A (ja) 2018-03-29
JP2018508580A5 JP2018508580A5 (cg-RX-API-DMAC7.html) 2019-04-11
JP6937984B2 true JP6937984B2 (ja) 2021-09-22

Family

ID=56848663

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017565038A Active JP6937984B2 (ja) 2015-03-03 2016-03-01 ペグ化ｉｌ−１１の組成物および方法
JP2021120139A Pending JP2021176875A (ja) 2015-03-03 2021-07-21 ポリエチレングリコール（ｐｅｇ）−インターロイキン１１（ｉｌ−１１）コンジュゲートを生成するための反応中間体、および、ｐｅｇ−ｉｌ−１１コンジュゲートを精製する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021120139A Pending JP2021176875A (ja) 2015-03-03 2021-07-21 ポリエチレングリコール（ｐｅｇ）−インターロイキン１１（ｉｌ−１１）コンジュゲートを生成するための反応中間体、および、ｐｅｇ−ｉｌ−１１コンジュゲートを精製する方法

Country Status (7)

Country Link
US (4) US10335492B2 (cg-RX-API-DMAC7.html)
EP (1) EP3265479A4 (cg-RX-API-DMAC7.html)
JP (2) JP6937984B2 (cg-RX-API-DMAC7.html)
CN (1) CN107849108A (cg-RX-API-DMAC7.html)
HK (1) HK1246306A1 (cg-RX-API-DMAC7.html)
TW (2) TWI849231B (cg-RX-API-DMAC7.html)
WO (1) WO2016140983A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI849231B (zh) * 2015-03-03 2024-07-21 香港商南沙生物科技（香港）有限公司 聚乙二醇化介白素-11之組合物及方法
KR20230045586A (ko) * 2021-09-28 2023-04-04 한양대학교 산학협력단 암 치료용 글리시리진-분지형 폴리에틸렌글리콜 컨쥬게이트
CN118388578B (zh) * 2024-04-01 2025-01-24 北京大学口腔医学院 一种用于聚乙二醇化蛋白质的方法、非共价聚乙二醇化蛋白及含有其的蛋白质药物和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
CN1316436A (zh) * 2000-04-06 2001-10-10 赵剑 水溶性缓释重组蛋白质的制备方法
MXPA05006945A (es) * 2002-12-26 2005-12-14 Mountain View Pharmaceuticals Conjugados polimericos de citoquinas, quimiocinas, factores de crecimiento, hormonas polipeptidicas y sus antagonistas con actividad conservada de union al receptor.
JP2005281302A (ja) * 2004-03-03 2005-10-13 Astellas Pharma Inc 修飾インターロイキン−１１及びそれを含有する医薬組成物
WO2005085283A1 (ja) * 2004-03-03 2005-09-15 Yamanouchi Pharmaceutical Co., Ltd. 修飾インターロイキン−１１及びそれを含有する医薬組成物
MX2011002055A (es) * 2008-08-25 2011-03-30 Viromed Co Ltd Conjugados de biopolimeros que contienen un analogo de interleucina-11.
JP2012528597A (ja) * 2009-06-03 2012-11-15 レガド・バイオサイエンシズ・インク 血小板グリコプロテインｖｉの核酸調節因子
JP5643824B2 (ja) * 2009-09-18 2014-12-17 プロセリクス メディスンズ ディベロプメント リミテッド 放出特性が改善されたｂａｂブロックポリマー
CA2798518A1 (en) * 2010-05-17 2011-11-24 Cebix, Inc. Pegylated c-peptide
US9023791B2 (en) * 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
WO2013020079A2 (en) 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer
WO2014008242A1 (en) 2012-07-03 2014-01-09 The Trustees Of Columbia University In The City Of New York The use of interleukin-11 to protect against ischemia and reperfusion injury
US8963121B2 (en) * 2012-12-07 2015-02-24 Micron Technology, Inc. Vertical solid-state transducers and high voltage solid-state transducers having buried contacts and associated systems and methods
WO2014138086A1 (en) 2013-03-05 2014-09-12 Shifa Biomedical Compositions and methods for the production of virus-like particles
CN109498815B (zh) * 2013-12-30 2022-07-22 江苏众红生物工程创药研究院有限公司 重组人激肽释放酶的化学修饰物及其应用
TWI849231B (zh) * 2015-03-03 2024-07-21 香港商南沙生物科技（香港）有限公司 聚乙二醇化介白素-11之組合物及方法

Also Published As

Publication number Publication date
US11931417B2 (en) 2024-03-19
US20190365908A1 (en) 2019-12-05
TWI708611B (zh) 2020-11-01
TWI849231B (zh) 2024-07-21
HK1246306A1 (zh) 2018-09-07
US10881739B2 (en) 2021-01-05
TW202103728A (zh) 2021-02-01
EP3265479A4 (en) 2018-11-14
US20190365909A1 (en) 2019-12-05
EP3265479A1 (en) 2018-01-10
US20210268117A1 (en) 2021-09-02
CN107849108A (zh) 2018-03-27
JP2018508580A (ja) 2018-03-29
US20180036418A1 (en) 2018-02-08
WO2016140983A1 (en) 2016-09-09
JP2021176875A (ja) 2021-11-11
US10335492B2 (en) 2019-07-02
US10946103B2 (en) 2021-03-16
TW201703793A (zh) 2017-02-01

Similar Documents

Publication Publication Date Title
JP4266028B2 (ja) エリスロポエチン受容体に結合する新規ペプチド
ES2395413T3 (es) Péptidos que se unen al receptor de eritropoyetina
EP2233504B1 (en) An erythropoietin mimetic peptide derivatives and its pharmaceutical salt, the preparation and uses thereof
JP2021176875A (ja) ポリエチレングリコール（ｐｅｇ）−インターロイキン１１（ｉｌ−１１）コンジュゲートを生成するための反応中間体、および、ｐｅｇ−ｉｌ−１１コンジュゲートを精製する方法
US20160213760A1 (en) Aprotinin-derived polypeptide-antibody conjugates
CN110603260B (zh) Npra激动剂、组合物及其用途
US20250115654A1 (en) Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof
CN115803338A (zh) C型利尿钠肽及其治疗急性肺损伤的方法
JP2025521100A (ja) 抗Ｎｅｃｔｉｎ－４抗体薬物複合体を含む医薬組成物及びその使用
JP2022519796A (ja) 抗ｐｃｓｋ９抗体を含む安定製剤
JP6005732B2 (ja) 非ペプチド性重合体−インスリン多量体及びその製造方法
KR20250164783A (ko) 펩티드의 공유 결합 변형을 위한 양이온성 지질
JP2012510518A (ja) 体液貯留障害を処置するための方法および組成物
JP2008519858A (ja) エリスロポエチンレセプターに結合する新規ペプチド
CN105085653A (zh) 一种促红细胞生成素模拟肽及其制备方法和应用
CN105367629B (zh) 一种促红细胞生成素模拟肽以及其制备方法和用途
KR20170069997A (ko) 미리스토일화된 렙틴-관련된 펩티드 및 이들의 용도
CN106554395B (zh) 一种长效促红细胞生成素模拟肽及其制备方法和应用
CN105837681B (zh) 一种促红细胞生成素模拟肽衍生物、其制备方法和用途
CN105085654A (zh) 一种促红细胞生成素模拟肽及其制备方法和应用
CN106279398A (zh) 一种促红细胞生成素模拟肽及其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190301

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210603

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210622

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210719

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210719

R150 Certificate of patent or registration of utility model

Ref document number: 6937984

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250